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Rising antibiotic resistance means that alternative antibacterial strategies are sorely needed. In this issue,
Zhu et al. (2015) report the use of a Caenorhabditis elegans model to validate the Pseudomonas aeruginosa
virulence factor LasB as a potential therapeutic target and to identify a LasB inhibitor with in vivo efficacy.The ever-increasing occurrence of antibi-
otic resistance in pathogenic bacteria is a
significant global public health threat.
With the development of resistance to
newly deployed antibiotics being almost
inevitable, and often occurring within
only a few months or years, alternative
antibacterial strategies are sorely needed.
One such strategy is the development
of therapeutic agents that target and
nullify bacterial virulence factors. The inhi-
bition of virulence factors would abolish
the ability of the bacteria to cause dam-
age to the host and thereby allow the
immune system to clear the infection.
Such an approach would also potentially
avoid the selective pressure exerted by
traditional microbicidal antibiotics and
lead to a reduced occurrence of resis-
tance evolution. Additionally, the non-
microbicidal, narrow-spectrum nature of
targeting virulence factors of pathogenic
bacteria has the added advantage of
potentially avoiding the detrimental ef-
fects caused by conventional antibiotics
on the gut microbiota (Clatworthy et al.,
2007). Examples of antivirulence com-
pounds include type III secretion system
(T3SS) inhibitors such as salicylidene
acylhydrazides and caminoside B, the
cholera toxin inhibitor Virstatin, and inhi-
bitors of lethal factor (LF) from Bacillus
anthracis (Zambelloni et al., 2015).
Pseudomonas aeruginosa is one of the
so-called ‘ESKAPE’ pathogens, high-Figure 1. N-Mercaptoacetyl-Phe-Tyr-Amide 1 and Thioacetate
Prodrug 2lighted by the Infectious
Diseases Society of America
(ISDA) as being the greatest
threat to human health
(Boucher et al., 2009). It is
the fifth most common noso-
comial pathogen isolated
and it is consistently asso-
ciated with the highest mor-
tality rate (50%–80%; Holder,
2004). P. aeruginosa pro-436 Chemistry & Biology 22, April 23, 2015 ªduces a number of virulence factors
including exotoxin A, pyocyanin, lipases,
and several proteases, one of which is
the elastase LasB (Gellatly and Hancock,
2013). LasB is a zinc metalloprotease
that enhances the pathogenicity of the
bacterium by several means. LasB
causes tissue destruction in the host,
and this destruction in turn liberates nutri-
ents, which causes acceleration in bacte-
rial growth. LasB also exerts an immuno-
modulatory effect and initiates biofilm
formation (Cathcart et al., 2011).
In their current manuscript, Janda and
coworkers report the in silico and in vitro
identification of the mercaptoacetamide
motif as an effective class of LasB inhi-
bitors. They also establish a powerful
organism infection model using Caeno-
rhabditis elegans that can be used to
rapidly understand the impact that bacte-
rial virulence factors (and their inhibition)
have in vivo (Zhu et al., 2015).
The mercaptoamide motif was first
investigated as a potential LasB inhibitor
by Cathcart et al. (2011), with screening
of a library of 400 peptides leading to
the identification of N-mercaptoacetyl-
Phe-Tyr-amide 1 (Figure 1) as a lead
inhibitor of LasB (Cathcart et al., 2011).
Reasoning that there is significant struc-
tural space around this motif that could
potentially be exploited for the develop-
ment of potent small molecule inhibitors
of LasB, Janda and coworkers (Zhu2015 Elsevier Ltd All rights reservedet al., 2015) performed docking experi-
ments between LasB and a library of com-
pounds containing the mercaptoamide
group. The efficacy of this screen was
then confirmed in vitro by screening a
subset of the library for LasB inhibition
activity. Analog synthesis was then per-
formed around a series of mercaptoa-
mides and led to the identification of
10 lead LasB antagonists. The three
most potent compounds, which exhibited
low micromolar IC50 values, were con-
verted to the corresponding thioacetates
in a prodrug approach to circumvent
the oxidative liability of the mercaptoace-
tamide motif and enable in vivo testing of
the inhibitors.
The importanceof LasB toP.aeruginosa
PAO1 virulence was then established
using a C. elegans disease model, where
infection with a lasB knockout mutant
was shown to result in an extended life
span of the worms and in lower levels
of host tissue damage as compared to
infection with wild-type PAO1. Thus, this
model organism provides a powerful
in vivo tool to rapidly assess the impact
small molecule modulation of virulence
factor function/production has in the
context of a multicellular host. This plat-
form provides many advantages over
mammalianmodels, as it is experimentally
tractable andmuch less costly to perform.
Thioacetate 2 (Figure 1) exhibited potent
activity, delivering the same degree ofvirulence attenuation as the
lasB knockout mutant. Com-
pound 2 also demonstrated
selectivity for LasB, with no
observed inhibition of the
ubiquitous metalloenzymes
matrix metalloproteinase 2
(MMP-2) and a Zn2+-depen-
dent histone deacetylase
(HDAC). ADME experiments
also established that the
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hydrolyzed to the active thiol and accumu-
lated in the worms in this form, thus vali-
dating the prodrug approach.
It is clear that with the rapid rise of
multidrug resistant infections, new and
innovative ways to combat bacterial
threats are needed. The manuscript by
Janda and coworkers (Zhu et al., 2015)
not only describes the identification and
characterization of a potent inhibitor of
LasB with in vivo efficacy, but also vali-
dates the relevance of LasB as an antivir-ulence target. Furthermore, the use of
a C. elegans disease model to identify
inhibitors of LasB has the potential to
translate to numerous other bacterial
virulence factors, opening up a new
pathway for the identification of much
needed alternative antibacterial agents.
REFERENCES
Boucher, H.W., Talbot, G.H., Bradley, J.S.,
Edwards, J.E., Gilbert, D., Rice, L.B., Scheld, M.,
Spellberg, B., and Bartlett, J. (2009). Clin. Infect.
Dis. 48, 1–12.Chemistry & Biology 22, April 23, 2015Cathcart, G.R., Quinn, D., Greer, B., Harriott, P.,
Lynas, J.F., Gilmore, B.F., and Walker, B. (2011).
Antimicrob. Agents Chemother. 55, 2670–2678.
Clatworthy, A.E., Pierson, E., and Hung, D.T.
(2007). Nat. Chem. Biol. 3, 541–548.
Gellatly, S.L., and Hancock, R.E. (2013). Pathog.
Dis. 67, 159–173.
Holder, I.A. (2004). Vaccine 22, 831–839.
Zambelloni, R., Marquez, R., and Roe, A.J. (2015).
Chem. Biol. Drug Des. 85, 43–55.
Zhu, J., Cai, X., Harris, T.L., Gooyit, M., Wood, M.,
Lardy, M., and Janda, K.D. (2015). Chem. Biol. 22,
this issue, 483–491.Tuberculosis Terpene TargetsEric Oldfield1,*
1Department of Chemistry, University of Illinois at Urbana-Champaign, 600 South Mathews Avenue, Urbana, IL 61801, USA
*Correspondence: eoldfiel@illinois.edu
http://dx.doi.org/10.1016/j.chembiol.2015.04.004
In this issue, Young, Moody, and colleagues report the discovery of an isomer of the Mycobacterium
tuberculosis (Mtb) virulence factor 1-tuberculosinyl adenosine,N6-tuberculosinyl adenosine, inmice infected
with tuberculosis. These Mtb-derived terpene compoundsmay serve as sensitive and specific biomarkers of
infection.With the rapid increase in antibiotic drug
resistance (Centers for Disease Control
and Prevention, 2013; World Health
Organization, 2014), there is renewed
interest in the development of new
approaches to rapid diagnostics (https://
www.longitudeprize.org/; https://www.
whitehouse.gov/the-press-office/2014/09/
18/executive-order-combating-antibiotic-
resistant-bacteria), as well as novel ap-
proaches to chemotherapy (Oldfield and
Feng, 2014). One approach to new
therapeutics is to target virulence factors.
Virulence factors are generally used
by bacterial and fungal pathogens
to circumvent host defenses, such as
those provided by neutrophils and
macrophages. One example is that of
the isoprenoid virulence factor, staphy-
loxanthin, in Staphylococcus aureus.
This polyene acts as a ‘‘shield’’ against
host defenses (reactive oxygen species)
and is a target for chemotherapy (Liu
et al., 2008). Another virulence factor
is the isoprenoid tuberculosinyl adeno-
sine (Layre et al., 2014), found in theorganism Mycobacterium tuberculosis
(Mtb), the causative agent of tuberculosis.
This diterpene virulence factor is synthe-
sized from the basic building blocks
of isoprenoid biosynthesis, isopentenyl
diphosphate (Figure 1, 1) and dimethylallyl
diphosphate (2), which condense to
form geranyl diphosphate (3), then farne-
syl diphosphate and geranylgeranyl
diphosphate (GGPP; 4), in reactions
carried out by a series of head-to-head
trans-prenyl synthases. In Mtb, GGPP
is then cyclized by a class II terpene
cyclase (Rv3377c) to form tuberculosinyl
diphosphate (5) (Nakano and Hoshino,
2009), which then alkylates adenosine
on the purine ring at N-1 to form
1-tuberculosinyl adenosine (1-TbAd; 6) in
a reaction catalyzed by tuberculosinyl
adenosine synthase (Rv3378c) (Layre
et al., 2014).
The story of 1-TbAd is a fairly lengthy
one, but in brief: In early work, it was
found that Mtb formed diterpenes, the
tuberculosinols that were later found to
have the same structure as the nosyber-kols extracted from a marine sponge (or
its inhabitants). Hoshino and coworkers
showed that the Rv3377c and Rv3378c
gene products were involved in the
production of these diterpenes, a particu-
larly interesting observation given that
in previous work, Pethe, Russell et al.
(Pethe et al., 2004) had shown that
these gene products were essential for
survival of Mtb inside macrophages.
These cells serve as Mtb’s normal host,
and the diterpene products most likely
accomplish this by preventing phago-
some acidification. These observations
lead to the idea that it might be possible
to kill Mtb inside macrophages by chemi-
cal inhibition of Rv3377c/Rv3378c (Mann
et al., 2009), an anti-virulence approach
to therapy.
Our group (Chan et al., 2014) as well as
Tom Alber’s group (Layre et al., 2014)
separately determined the structure
of Rv3378c, finding that, consistent
with earlier computational predictions,
it adopted the cis-prenyl transferase fold
found in the proteins decaprenylª2015 Elsevier Ltd All rights reserved 437
